Difference between revisions of "Ramucirumab (Cyramza)"
Jump to navigation
Jump to search
| Line 27: | Line 27: | ||
===[[Hepatocellular carcinoma]]=== | ===[[Hepatocellular carcinoma]]=== | ||
| − | * 5/10/2019: Approved as a single agent for [[Hepatocellular carcinoma|hepatocellular carcinoma (HCC)]] in patients who have an alpha fetoprotein (AFP) of at least 400 ng/mL and have been previously treated with sorafenib. ''(New disease approval)'' | + | * 5/10/2019: Approved as a single agent for [[Hepatocellular carcinoma|hepatocellular carcinoma (HCC)]] in patients who have an [[Biomarkers#AFP|alpha fetoprotein (AFP)]] of at least 400 ng/mL and have been previously treated with sorafenib. ''(New disease approval)'' |
===[[Non-small cell lung cancer]]=== | ===[[Non-small cell lung cancer]]=== | ||
* 12/12/2014: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm426735.htm Approved] for use in combination with [[Docetaxel (Taxotere)|docetaxel]] for the treatment of patients with metastatic [[Non-small cell lung cancer | non-small cell lung cancer (NSCLC)]] with disease progression on or after [[Regimen_classes#Platinum-based_regimen|platinum-based chemotherapy]]. ''(New disease approval)'' | * 12/12/2014: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm426735.htm Approved] for use in combination with [[Docetaxel (Taxotere)|docetaxel]] for the treatment of patients with metastatic [[Non-small cell lung cancer | non-small cell lung cancer (NSCLC)]] with disease progression on or after [[Regimen_classes#Platinum-based_regimen|platinum-based chemotherapy]]. ''(New disease approval)'' | ||
| − | * 5/29/2020: Approved in combination with erlotinib for first-line treatment of metastatic [[Non-small cell lung cancer | non-small cell lung cancer (NSCLC)]] with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ''(Approval expanded to first-line setting in EGFR+ NSCLC)'' | + | * 5/29/2020: Approved in combination with erlotinib for first-line treatment of metastatic [[Non-small cell lung cancer | non-small cell lung cancer (NSCLC)]] with [[Biomarkers#EGFR|epidermal growth factor receptor (EGFR)]] [[Biomarkers#Exon_19|exon 19]] [[#Biomarkers_Structural Variant|deletions]] or [[Biomarkers#L858R|exon 21 (L858R) mutations]]. ''(Approval expanded to first-line setting in EGFR+ NSCLC)'' |
==Also known as== | ==Also known as== | ||
Revision as of 00:45, 13 April 2021
General information
Class/mechanism: Recombinant human IgG1 monoclonal antibody, VEGFR2 (vascular endothelial growth factor receptor 2) antagonist. Ramucirumab binds VEGFR2 and blocks VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D, which inhibits angiogenesis.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Ramucirumab (Cyramza) patient drug information (Chemocare)[4]
- Ramucirumab (Cyramza) package insert[1]
- Ramucirumab (Cyramza) patient drug information (UpToDate)[5]
History of changes in FDA indication
Colorectal cancer
- 4/24/2015: Approved in combination with FOLFIRI, for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. (New disease approval)
Gastric cancer
- 4/21/2014: Initial approval for the treatment of patients with advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine- or platinum- containing chemotherapy.
- 11/5/2014: Approval and indication expanded for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. (Requirement for prior lines of treatment removed)
Hepatocellular carcinoma
- 5/10/2019: Approved as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of at least 400 ng/mL and have been previously treated with sorafenib. (New disease approval)
Non-small cell lung cancer
- 12/12/2014: Approved for use in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. (New disease approval)
- 5/29/2020: Approved in combination with erlotinib for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. (Approval expanded to first-line setting in EGFR+ NSCLC)
Also known as
- Code names: IMC-1121B, LY3009806
- Brand name: Cyramza
References
Categories:
- Drugs
- Intravenous medications
- Mutation-specific medications
- Protein expression-specific medications
- Anti-VEGFR antibodies
- VEGFR inhibitors
- Bladder cancer medications
- Colon cancer medications
- Gastric cancer medications
- Hepatocellular carcinoma medications
- Non-small cell lung cancer medications
- FDA approved in 2014
- PMDA approved drugs